Endosc Int Open 2014; 02(03): E153-E159
DOI: 10.1055/s-0034-1377523
Original article
© Georg Thieme Verlag KG Stuttgart · New York

A pilot study of EUS-guided fiducial insertion for the multidisciplinary management of gastric cancer

Sujievvan Chandran
1   Austin Health—Gastroenterology, Melbourne, Victoria, Australia
,
Rhys Vaughan
1   Austin Health—Gastroenterology, Melbourne, Victoria, Australia
,
Marios Efthymiou
1   Austin Health—Gastroenterology, Melbourne, Victoria, Australia
,
Joseph Sia
2   Austin Health—Radiation Oncology, Melbourne, Victoria, Australia
,
Christopher Hamilton
2   Austin Health—Radiation Oncology, Melbourne, Victoria, Australia
› Author Affiliations
Further Information

Publication History

submitted 21 May 2014

accepted after revision 03 June 2014

Publication Date:
18 July 2014 (online)

Background and study aims: The 5-year survival rates for gastric cancer remain poor despite evolving therapies, and fiducial insertion via endoscopic ultrasound (EUS) is novel within this setting. We aimed to assess the feasibility of fiducial insertion for response assessment and anatomic localization in patients with gastric cancer.

Patients and methods: A prospective phase II feasibility study was undertaken at Austin Health (Victoria, Australia) from February 2011 to November 2012. Consecutive adult patients were enrolled who had primary adenocarcinoma of the stomach with American Joint Committee on Cancer stage T1 – 3,N0 – 1,M0 – 1a and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. In addition, the patients were medically suitable for gastrectomy and chemotherapy/chemoradiotherapy. Gold fiducial markers were inserted under EUS guidance into the margins of the gastric cancer primary. The main outcome was successful insertion of the fiducial without complications for response assessment and anatomic localization.

Results: A total of 15 fiducials were successfully inserted into 7 (88 %) of 8 patients. No immediate or delayed complications were noted. One patient proceeded to image-guided radiotherapy through the use of fiducials and is disease free at 12 months. Fiducials were used to assess treatment response in all patients who underwent computed tomographic imaging after insertion. Follow-up computed tomography with fiducial placement improved anatomic localization and estimation of the gastric cancer primary size in 3 (60 %) of 5 patients.

Conclusions: Within the limitations of our small study cohort, fiducials were placed in gastric cancers under EUS guidance without complications, and placement was successful in the majority of our patients. Although potential benefits exist, there remain substantial limitations to the generalization of this technique across our patient population.

 
  • References

  • 1 Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia: an overview. Cancer series no. 46. Cat no. CAN 42. Canberra: AIHW; 2008
  • 2 Chong G, Tebbutt NC. Perioperative therapy for resectable gastric cancer: what does the future hold?. Asia Pac J Clin Oncol 2011; 7: 93-95
  • 3 Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530
  • 4 Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077
  • 5 Shirato H, Harada T, Harabayashi T et al. Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 240-247
  • 6 Hashimoto T, Shirato H, Kato M et al. Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys 2005; 61: 1559-1564
  • 7 Pishvaian AC, Collins B, Gagnon G et al. EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. Gastrointest Endosc 2006; 64: 412-417
  • 8 DiMaio CJ, Nagula S, Goodman KA et al. EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with videos). Gastrointest Endosc 2010; 71: 1204-1210
  • 9 Varadarajulu S, Trevino JM, Shen S et al. The use of endoscopic ultrasound-guided gold markers in image-guided radiation therapy of pancreatic cancers: a case series. Endoscopy 2010; 42: 423-425
  • 10 Singh J, Greer PB, White MA et al. Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys 2013; 85: 1018-1023
  • 11 Kirby AN, Jena R, Harris EJ et al. Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers?. Radiother Oncol 2013; 106: 231-235
  • 12 Ellsmere JC, Mahadevan A, Kelleher T et al. EUS-guided radiotherapy fiducials for upper gastrointestinal malignancies. Gastrointest Endosc 2007; 65: AB208
  • 13 Edge SB, Byrd DR, Compton CC et al. American Joint Committee on Cancer staging manual. 7th. edn. New York, NY: Springer; 2010
  • 14 Joon DL, Khoo V, Mercuri A et al. AllProstate radiotherapy: is one or two gold seeds equivalent to three?. Paper presented at: 94th Scientific Assembly and Annual Meeting of the Radiation Society of North America December 2, 2008 http://archive.rsna.org/2008/7000407.html (Accessed 4 June 2014)
  • 15 Kudchadker RJ, Lee AK, Yu ZH et al. Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys 2009; 74: 1283-1289
  • 16 Park WG, Yan BM, Schellenberg D et al. EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc 2010; 71: 513-518
  • 17 Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol 2007; 14: 2687-2690
  • 18 Klautke G, Fietkau R. Significance of radiation therapy for adenocarcinomas of the esophagus, gastroesophageal junction and gastric cancer with special reference to the MAGIC trial. Strahlenther Onkol 2007; 183: 163-169
  • 19 Habermann CR, Weiss F, Riecken R et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology 2004; 230: 465-471
  • 20 Chen CY, Hsu JS, Wu DC et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT—correlation with surgical and histopathologic results. Radiology 2007; 242: 472-482
  • 21 D'Elia F, Zingarelli A, Palli D et al. Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases. Eur Radiol 2000; 10: 1877-1885
  • 22 Draganov PV, Chavalitdhamrong D, Wagh MS. Evaluation of a new endoscopic ultrasound-guided multi-fiducial delivery system: a prospective non-survival study in a live porcine model. Dig Endosc 2013; 25: 615-621
  • 23 Ganpathi IS, So JB, Ho KY. Endoscopic ultrasonography for gastric cancer: does it influence treatment?. Surg Endosc 2006; 20: 559-562
  • 24 Cardoso R, Coburn N, Seevaratnam R et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer 2012; 15: S19-S26